In a nutshell This study examined evidence for the benefits of adding chemotherapy early to hormone therapy for metastatic prostate cancer. Authors concluded that early evidence indicates a survival benefit with the addition of chemotherapy for metastatic prostate cancer. Some background Androgen deprivation therapy (ADT) is a type of hormone...
Read MoreIn a nutshell This study examined whether the duration of primary (first round) hormone therapy impacts abiraterone (Zytiga) treatment for metastatic castration-resistant prostate cancer (mCRPC). Researchers concluded that the benefits of abiraterone were not dependent on the duration of primary hormone therapy. Some background Androgen...
Read More
Are there any immunotherapy approaches currently available to advanced prostate cancer patients? Patient Power Founder and Host, Andrew Schorr, leads a discussion with prostate cancer experts Dr. William Catalona of Lurie Cancer Center and Dr. Russell Szmulewitz on immunotherapy research. Dr. Szmulewitz gives a short account of immunology...
Read More
In a nutshell This study examined the benefit of adding chemotherapy to androgen deprivation therapy (ADT) early to treat metastatic hormone-sensitive prostate cancer. Researchers reported a survival benefit when chemotherapy was added to ADT. This benefit was only detected with chemotherapy involving docetaxel (Taxotere). Some background ADT is a...
Read More
What are the common side effects of advanced prostate cancer treatment, and how can they be managed? An expert panel—including Dr. Jeri Kim, Dr. Sumit Subudhi and Zita Dubauskas Lim—shares an overview of side effects associated with hormonal therapies, chemotherapy and immunotherapy. Published By : Patient Power Date : Aug 18,...
Read More
In a nutshell This phase 2 trial aims to compare the benefit of two types of exercise for men with metastatic castration-resistant prostate cancer. The main outcome to be investigated is the safety of the exercises and its effect on cancer pain. The trial is recruiting in San Francisco (California). The details Metastatic castration-resistant...
Read MoreIn a nutshell This study examined treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) progressing after treatment with abiraterone acetate (Zytiga). Chemotherapy with docetaxel (Taxotere) was the most common subsequent therapy. Authors concluded that patients with mCRPC who progress after AA may still benefit from subsequent...
Read MoreIn a nutshell This study investigated the benefit of local therapies as first-line interventions for metastatic prostate cancer. Authors reported improved survival with radiation and surgery among men with metastatic prostate cancer at diagnosis. Some background Metastatic prostate cancer is cancer that has spread to distant parts of the body. The...
Read More
In a nutshell This study investigated cabozantinib (Cometriq), an anti-angiogenic drug, in the treatment of advanced and progressing prostate cancer. Researchers report preliminary evidence for cabozantinib in reducing disease progression and cancer pain. Some background Tumors need to be able to grow new blood vessels in order to grow....
Read MoreIn a nutshell This review examined intermittent and continuous docetaxel (Taxotere) treatment for metastatic castration-resistant prostate cancer (mCRPC). Researchers concluded that intermittent docetaxel treatment can be a feasible treatment option in the management of mCRPC. Some background Chemotherapy with docetaxel is often the first-line...
Read More
Diagnosed with advanced prostate cancer at age 53, Joe felt like he was hit by a Mac truck and prepared for the worst. Now, five years later, Joe is doing well and his PSA is undetectable. Joe and his wife, Yolanda, share their story and explain the tools that helped Joe move past the initial fear of his diagnosis. Transcript Please...
Read More
How does a diagnosis of prostate cancer affect intimacy? Led by patient advocate Jeff Folloder, experts across several disciplines discuss sexuality and dysfunction. The panel explores how, in one form or another, this subject affects every single advanced prostate cancer patient and his partner. Learn how communication and support through...
Read More
